Palvella Therapeutics Inc (PVLA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PVLA Annual Balance Sheets →
The balance sheet figures below highlight longer-term patterns in how Palvella Therapeutics Inc finances operations and invests in assets.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent250.60
Short-term Investments, Total62.78
Cash & Short-term Investments312.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current2.44
Total Current Assets253.03
Other Assets, Noncurrent0.48
Operating Lease Right Of Use Asset0.53
Total Assets253.51
Liabilities
Accounts Payable, Current AC6.79
Accrued Liabilities, Current1.47
Derivative Liability, Current DE0.00
Other Liabilities, Current3.69
Total Current Liabilities11.95
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE2.27
Other liabilities, Noncurrent22.43
Accrued Liabilities And Other Liabilities Current3.46
Total Liabilities36.64
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock389.85
Retained Earnings / Accumulated Deficit-173.09
Accumulated Other Comprehensive Income0.09
Other Equity0.09
Common Stockholder's Equity216.87
Total Stockholder's Equity216.87
Liabilities & Stockholder's Equity253.51
4 historic quarters locked

Sign in to unlock the full Palvella Therapeutics Inc balance sheet history.

About Palvella Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-331574

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.